Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan

Tetsuhide Ito, Hironobu Sasano, Masao Tanaka, R. Yoshiyuki Osamura, Iwao Sasaki, Wataru Kimura, Koji Takano, Takao Obara, Miyuki Ishibashi, Kazuwa Nakao, Ryuichiro Doi, Akira Shimatsu, Toshirou Nishida, Izumi Komoto, Yukio Hirata, Kazuhiko Nakamura, Hisato Igarashi, Robert T. Jensen, Bertram Wiedenmann, Masayuki Imamura

Research output: Contribution to journalArticle

219 Citations (Scopus)

Abstract

Background: There have been few epidemiological studies on gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Japan. Methods: We examined the epidemiology of GEP-NETs [pancreatic endocrine tumors (PETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005 using a nationwide stratified random sampling method. Results: A total of 2,845 individuals received treatment for PETs. Prevalence was estimated as 2.23/100,000 with an annual onset incidence of 1.01/100,000. Non-functioning tumor (NF)-PET constituted 47.4%, followed by insulinoma (38.2%) and gastrinoma (7.9%). Distant metastases were reported in 21% patients with NF-PETs and occurred more frequently as tumor size increased (>2 cm). Multiple endocrine neoplasia type 1 (MEN-1) was detected in 10% of PETs but only in 6.1% of NF-PETs. NF-PETs were detected incidentally by physical examination in 24% patients. In 2005, an estimated 4,406 patients received treatment for GI-NETs. Prevalence was estimated as 3.45/100,000, with an annual onset incidence of 2.10/100,000. The locations of GI-NETs varied: foregut, 30.4%; midgut, 9.6%; and hindgut, 60.0%. Distant metastases were observed in 6%. Lymph node metastases occurred more frequently as tumor size increased (>1 cm). The frequency of MEN-1 complications was 1%. Physical examination revealed GI-NETs in 44% patients. The frequency of symptomatic GI-NETs was 3.4%. Interestingly, 77.1% of patients with foregut GI-NETs had type A gastritis. Conclusion: Our results show there are large differences in GEP-NETs between Japan and Western nations, primarily due to differences in the presence of MEN-1 in NF-PETs and the location, symptomatic status, and prevalence of malignancy in GI-NETs.

Original languageEnglish
Pages (from-to)234-243
Number of pages10
JournalJournal of gastroenterology
Volume45
Issue number2
DOIs
Publication statusPublished - Feb 1 2010

Fingerprint

Epidemiologic Studies
Japan
Neuroendocrine Tumors
Neoplasms
Multiple Endocrine Neoplasia Type 1
Neoplasm Metastasis
Physical Examination
Gastro-enteropancreatic neuroendocrine tumor
Gastrinoma
Insulinoma
Incidence
Gastritis
Epidemiology
Lymph Nodes
Non functioning pancreatic endocrine tumor
Therapeutics

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Ito, T., Sasano, H., Tanaka, M., Osamura, R. Y., Sasaki, I., Kimura, W., ... Imamura, M. (2010). Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. Journal of gastroenterology, 45(2), 234-243. https://doi.org/10.1007/s00535-009-0194-8

Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. / Ito, Tetsuhide; Sasano, Hironobu; Tanaka, Masao; Osamura, R. Yoshiyuki; Sasaki, Iwao; Kimura, Wataru; Takano, Koji; Obara, Takao; Ishibashi, Miyuki; Nakao, Kazuwa; Doi, Ryuichiro; Shimatsu, Akira; Nishida, Toshirou; Komoto, Izumi; Hirata, Yukio; Nakamura, Kazuhiko; Igarashi, Hisato; Jensen, Robert T.; Wiedenmann, Bertram; Imamura, Masayuki.

In: Journal of gastroenterology, Vol. 45, No. 2, 01.02.2010, p. 234-243.

Research output: Contribution to journalArticle

Ito, T, Sasano, H, Tanaka, M, Osamura, RY, Sasaki, I, Kimura, W, Takano, K, Obara, T, Ishibashi, M, Nakao, K, Doi, R, Shimatsu, A, Nishida, T, Komoto, I, Hirata, Y, Nakamura, K, Igarashi, H, Jensen, RT, Wiedenmann, B & Imamura, M 2010, 'Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan', Journal of gastroenterology, vol. 45, no. 2, pp. 234-243. https://doi.org/10.1007/s00535-009-0194-8
Ito, Tetsuhide ; Sasano, Hironobu ; Tanaka, Masao ; Osamura, R. Yoshiyuki ; Sasaki, Iwao ; Kimura, Wataru ; Takano, Koji ; Obara, Takao ; Ishibashi, Miyuki ; Nakao, Kazuwa ; Doi, Ryuichiro ; Shimatsu, Akira ; Nishida, Toshirou ; Komoto, Izumi ; Hirata, Yukio ; Nakamura, Kazuhiko ; Igarashi, Hisato ; Jensen, Robert T. ; Wiedenmann, Bertram ; Imamura, Masayuki. / Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. In: Journal of gastroenterology. 2010 ; Vol. 45, No. 2. pp. 234-243.
@article{2e7077626dbb4bfd81ab6fe2a2022463,
title = "Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan",
abstract = "Background: There have been few epidemiological studies on gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Japan. Methods: We examined the epidemiology of GEP-NETs [pancreatic endocrine tumors (PETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005 using a nationwide stratified random sampling method. Results: A total of 2,845 individuals received treatment for PETs. Prevalence was estimated as 2.23/100,000 with an annual onset incidence of 1.01/100,000. Non-functioning tumor (NF)-PET constituted 47.4{\%}, followed by insulinoma (38.2{\%}) and gastrinoma (7.9{\%}). Distant metastases were reported in 21{\%} patients with NF-PETs and occurred more frequently as tumor size increased (>2 cm). Multiple endocrine neoplasia type 1 (MEN-1) was detected in 10{\%} of PETs but only in 6.1{\%} of NF-PETs. NF-PETs were detected incidentally by physical examination in 24{\%} patients. In 2005, an estimated 4,406 patients received treatment for GI-NETs. Prevalence was estimated as 3.45/100,000, with an annual onset incidence of 2.10/100,000. The locations of GI-NETs varied: foregut, 30.4{\%}; midgut, 9.6{\%}; and hindgut, 60.0{\%}. Distant metastases were observed in 6{\%}. Lymph node metastases occurred more frequently as tumor size increased (>1 cm). The frequency of MEN-1 complications was 1{\%}. Physical examination revealed GI-NETs in 44{\%} patients. The frequency of symptomatic GI-NETs was 3.4{\%}. Interestingly, 77.1{\%} of patients with foregut GI-NETs had type A gastritis. Conclusion: Our results show there are large differences in GEP-NETs between Japan and Western nations, primarily due to differences in the presence of MEN-1 in NF-PETs and the location, symptomatic status, and prevalence of malignancy in GI-NETs.",
author = "Tetsuhide Ito and Hironobu Sasano and Masao Tanaka and Osamura, {R. Yoshiyuki} and Iwao Sasaki and Wataru Kimura and Koji Takano and Takao Obara and Miyuki Ishibashi and Kazuwa Nakao and Ryuichiro Doi and Akira Shimatsu and Toshirou Nishida and Izumi Komoto and Yukio Hirata and Kazuhiko Nakamura and Hisato Igarashi and Jensen, {Robert T.} and Bertram Wiedenmann and Masayuki Imamura",
year = "2010",
month = "2",
day = "1",
doi = "10.1007/s00535-009-0194-8",
language = "English",
volume = "45",
pages = "234--243",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan

AU - Ito, Tetsuhide

AU - Sasano, Hironobu

AU - Tanaka, Masao

AU - Osamura, R. Yoshiyuki

AU - Sasaki, Iwao

AU - Kimura, Wataru

AU - Takano, Koji

AU - Obara, Takao

AU - Ishibashi, Miyuki

AU - Nakao, Kazuwa

AU - Doi, Ryuichiro

AU - Shimatsu, Akira

AU - Nishida, Toshirou

AU - Komoto, Izumi

AU - Hirata, Yukio

AU - Nakamura, Kazuhiko

AU - Igarashi, Hisato

AU - Jensen, Robert T.

AU - Wiedenmann, Bertram

AU - Imamura, Masayuki

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Background: There have been few epidemiological studies on gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Japan. Methods: We examined the epidemiology of GEP-NETs [pancreatic endocrine tumors (PETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005 using a nationwide stratified random sampling method. Results: A total of 2,845 individuals received treatment for PETs. Prevalence was estimated as 2.23/100,000 with an annual onset incidence of 1.01/100,000. Non-functioning tumor (NF)-PET constituted 47.4%, followed by insulinoma (38.2%) and gastrinoma (7.9%). Distant metastases were reported in 21% patients with NF-PETs and occurred more frequently as tumor size increased (>2 cm). Multiple endocrine neoplasia type 1 (MEN-1) was detected in 10% of PETs but only in 6.1% of NF-PETs. NF-PETs were detected incidentally by physical examination in 24% patients. In 2005, an estimated 4,406 patients received treatment for GI-NETs. Prevalence was estimated as 3.45/100,000, with an annual onset incidence of 2.10/100,000. The locations of GI-NETs varied: foregut, 30.4%; midgut, 9.6%; and hindgut, 60.0%. Distant metastases were observed in 6%. Lymph node metastases occurred more frequently as tumor size increased (>1 cm). The frequency of MEN-1 complications was 1%. Physical examination revealed GI-NETs in 44% patients. The frequency of symptomatic GI-NETs was 3.4%. Interestingly, 77.1% of patients with foregut GI-NETs had type A gastritis. Conclusion: Our results show there are large differences in GEP-NETs between Japan and Western nations, primarily due to differences in the presence of MEN-1 in NF-PETs and the location, symptomatic status, and prevalence of malignancy in GI-NETs.

AB - Background: There have been few epidemiological studies on gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Japan. Methods: We examined the epidemiology of GEP-NETs [pancreatic endocrine tumors (PETs) and gastrointestinal neuroendocrine tumors (GI-NETs)] in Japan in 2005 using a nationwide stratified random sampling method. Results: A total of 2,845 individuals received treatment for PETs. Prevalence was estimated as 2.23/100,000 with an annual onset incidence of 1.01/100,000. Non-functioning tumor (NF)-PET constituted 47.4%, followed by insulinoma (38.2%) and gastrinoma (7.9%). Distant metastases were reported in 21% patients with NF-PETs and occurred more frequently as tumor size increased (>2 cm). Multiple endocrine neoplasia type 1 (MEN-1) was detected in 10% of PETs but only in 6.1% of NF-PETs. NF-PETs were detected incidentally by physical examination in 24% patients. In 2005, an estimated 4,406 patients received treatment for GI-NETs. Prevalence was estimated as 3.45/100,000, with an annual onset incidence of 2.10/100,000. The locations of GI-NETs varied: foregut, 30.4%; midgut, 9.6%; and hindgut, 60.0%. Distant metastases were observed in 6%. Lymph node metastases occurred more frequently as tumor size increased (>1 cm). The frequency of MEN-1 complications was 1%. Physical examination revealed GI-NETs in 44% patients. The frequency of symptomatic GI-NETs was 3.4%. Interestingly, 77.1% of patients with foregut GI-NETs had type A gastritis. Conclusion: Our results show there are large differences in GEP-NETs between Japan and Western nations, primarily due to differences in the presence of MEN-1 in NF-PETs and the location, symptomatic status, and prevalence of malignancy in GI-NETs.

UR - http://www.scopus.com/inward/record.url?scp=77949261439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949261439&partnerID=8YFLogxK

U2 - 10.1007/s00535-009-0194-8

DO - 10.1007/s00535-009-0194-8

M3 - Article

C2 - 20058030

AN - SCOPUS:77949261439

VL - 45

SP - 234

EP - 243

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 2

ER -